Skip to content
Testolactone
Teslac (testolactone) is a small molecule pharmaceutical. Testolactone was first approved as Teslac on 1982-01-01. It is used to treat breast neoplasms in the USA. The pharmaceutical is active against aromatase.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
skin and connective tissue diseasesD017437
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Testolactone
Tradename
Company
Number
Date
Products
TESLACBristol Myers SquibbN-016118 DISCN1982-01-01
2 products
TESLACBristol Myers SquibbN-016119 DISCN1982-01-01
1 products
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
breast neoplasmsEFO_0003869D001943C50
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
18 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
HivD006678O98.71——124
Hiv-associated lipodystrophy syndromeD039682EFO_1001348———112
Laron syndromeD046150Orphanet_633E34.321———1—1
Body compositionD001823———1—1
Diabetic retinopathyD003930EFO_0003770———1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
LipodystrophyD008060E88.1——2—13
Hiv infectionsD015658EFO_0000764B20——2——2
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Abdominal obesityD056128HP_0001956—1——12
Non-alcoholic fatty liver diseaseD065626EFO_0003095K75.81—1——12
Cognitive dysfunctionD060825G31.84—2———2
Type 2 diabetes mellitusD003924EFO_0001360E11—1———1
ObesityD009765EFO_0001073E66.9—1———1
Fatty liverD005234—1———1
AgingD000375GO_0007568R41.81—1———1
Peripheral nerve injuriesD059348—1———1
Traumatic brain injuriesD000070642S06—1———1
Sleep wake disordersD012893G47—1———1
Show 1 more
Indications Phases 1
No data
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients—————11
Hiv-2D015498————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameTESTOLACTONE
INNtestolactone
Description
Testolactone is a seco-androstane and a 3-oxo-Delta(1),Delta(4)-steroid.
Classification
Small molecule
Drug classAromatase inhibitor; Antiestrogen
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CCC(=O)O2
Identifiers
PDB—
CAS-ID968-93-4
RxCUI10378
ChEMBL IDCHEMBL1571
ChEBI ID9460
PubChem CID13769
DrugBankDB00894
UNII ID6J9BLA949Q (ChemIDplus, GSRS)
Target
Agency Approved
CYP19A1
CYP19A1
Organism
Homo sapiens
Gene name
CYP19A1
Gene synonyms
ARO1, CYAR, CYP19
NCBI Gene ID
1588
Protein name
aromatase
Protein synonyms
CYPXIX, Cytochrome P-450AROM, Cytochrome P450 19A1, cytochrome P450, family 19, subfamily A, polypeptide 1, cytochrome P450, subfamily XIX (aromatization of androgens), Estrogen synthase, estrogen synthetase, flavoprotein-linked monooxygenase, microsomal monooxygenase
Uniprot ID
Q8IYJ7
Mouse ortholog
Cyp19a1 (13075)
aromatase (P28649)
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 262 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
1,302 adverse events reported
View more details